Ana Sayfa Biyoteknoloji IMIGLIPTIN, New Patent, WO 2017211293, XUANZHU PHARMA CO., LTD.

IMIGLIPTIN, New Patent, WO 2017211293, XUANZHU PHARMA CO., LTD.

Dipeptidil Peptidan-4 ( DPP-4 ) inhibitörleri  son yıllarda  kullanıma  girmiş olan ,glisemik kontrolü  sağlamak  amaçlı kullanılan  ürünlerdir.
Bu  grupta  Xuanzhu  isimli  çin kökenli  firma  aşağıdaki  patenti  aldı.
Çin kısaca atılım içinde…..
XUANZHU PHARMA CO., LTD. [CN/CN]; 2518, Tianchen Street, National High-Tech Development Zone Jinan, Shandong 250101 (CN)
IMIGLIPTIN, New Patent, WO 2017211293, XUANZHU PHARMA CO., LTD.
The present invention relates to a crystalline form of a succinate used as a dipeptidyl peptidase-4 inhibitor, and a manufacturing method, pharmaceutical composition, and application thereof. The invention specifically relates to a dipeptidyl peptidase-4 inhibitor compound as represented by formula (1), a crystalline form of a succinate, wherein the succinate is an (R)-2-((7-(3-aminopiperidin-1-yl)-3,5-dimethyl-2-oxo-2,3-dihydro-1H-imidazo(4,5-b)pyridin-1-yl)methyl)benzonitrile, and a manufacturing method, pharmaceutical composition, and application thereof.